> Details

Elsayed, Mohamed; Abdel-kahaar, Emaad; Gahr, Maximilian; Connemann, Bernhard J.; Denkinger, Michael; Schönfeldt-Lecuona, Carlos

Arrhythmias related to antipsychotics and antidepressants: an analysis of the summaries of product characteristics of original products approved in Germany

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Arrhythmias related to antipsychotics and antidepressants: an analysis of the summaries of product characteristics of original products approved in Germany
  • Contributor: Elsayed, Mohamed; Abdel-kahaar, Emaad; Gahr, Maximilian; Connemann, Bernhard J.; Denkinger, Michael; Schönfeldt-Lecuona, Carlos
  • imprint: Springer Science and Business Media LLC, 2021
  • Published in: European Journal of Clinical Pharmacology
  • Language: English
  • DOI: 10.1007/s00228-020-03049-x
  • ISSN: 0031-6970; 1432-1041
  • Keywords: Pharmacology (medical) ; Pharmacology ; General Medicine
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title><jats:sec> <jats:title>Purpose</jats:title> <jats:p>Most psychiatric drugs, such as antidepressants (AD) and antipsychotics (AP), may cause cardiac adverse events (CAE). We used summaries of product characteristics (SmPC) for assessing the likelihood of AD and AP to cause CAE.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>We identified all original medicinal products (OMP) of AD and AP approved in Germany. We searched for their SmPCs using the online services of PharmaNet.Bund, Gelbe liste®, Rote Liste®, Fachinfo-Service®, and via manufacturer contact. We extracted frequencies of reported CAE (QT prolongation, Torsade de Pointes tachycardia, and ventricular arrhythmia) and performed a risk assessment.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>We obtained the SmPCs of 24 AD and 26 AP identified as OMP. Comparably high reported frequencies regarding QT prolongation were found for Invega® (paliperidone), Serdolect® (sertindole) (≥ 1/100 and &lt; 1/10), and Zoloft® (sertraline) (≥ 1/10.000 and &lt; 1/1000); regarding Torsade de Pointes tachycardia were found for Serdolect® (≥ 1/1000 to &lt; 1/100), Zoloft®, and Trevilor® (venlafaxine) (≥ 1/10.000 and &lt; 1/1000); regarding ventricular tachycardia for Solian® (amisulpride), Xomolix® (droperidol), Zyprexa® (olanzapine), and Trevilor® (≥ 1/10.000 and &lt; 1/1000).</jats:p> </jats:sec><jats:sec> <jats:title>Conclusion</jats:title> <jats:p>The risk and frequency of CAE, as reported in the SmPCs, varied significantly among substances and between groups. There are more reports for AP than AD. The AP with the most frequently reported CAE (QT prolongation and Torsade de Pointes tachycardia) was Serdolect®; for AD, Zoloft® (QT prolongation, Torsade de Pointes tachycardia) and Trevilor® (Torsade de Pointes tachycardia and ventricular tachycardia) carried a higher cardiac risk.</jats:p> </jats:sec>